Loss of VHL-mediated pRb regulation promotes clear cell renal cell carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• The von Hippel-Lindau (VHL) tumor suppressor is crucial in E3 ubiquitin ligase complexes, targeting substrates for proteasomal degradation.
• VHL inactivation is common in clear cell renal cell carcinoma (ccRCC), leading to stabilization of hypoxia-inducible factors (HIFs) and promoting tumor growth.
• While HIFα is a known VHL target, other HIF-independent VHL substrates and their roles in oncogenesis are less understood.

Purpose of the Study:

• To identify novel substrates of the VHL tumor suppressor.
• To elucidate the functional consequences of VHL inactivation on these novel substrates in ccRCC.
• To explore potential therapeutic strategies targeting the VHL pathway in ccRCC.

Main Methods:

• Utilized proximity labeling to identify proteasomal-sensitive VHL interactors.
• Investigated the interaction between VHL and retinoblastoma protein (pRb) and its effect on pRb degradation.
• Assessed the functional impact of pRb hyperstabilization in ccRCC cells and in vivo models.

Main Results:

• Identified retinoblastoma protein (pRb) as a novel substrate of VHL, promoting its ubiquitin-mediated degradation.
• Demonstrated that VHL inactivation leads to pRb hyperstabilization in ccRCC.
• Showed that loss of pRb in ccRCC results in increased cell death, altered transcription, and reduced oncogenic properties.
• Linked downstream transcriptional changes from pRb hyperstabilization to ccRCC development.

Conclusions:

• Revealed a novel VHL-pRb pathway implicated in ccRCC pathogenesis.
• Established pRb as a key VHL target contributing to ccRCC development independently of HIFα.
• Highlighted the VHL-pRb axis as a potential therapeutic target for inhibiting ccRCC progression.